← Eichor
Study identifier: NCT07141004 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

Condition: Arthritis, Psoriatic  ·  Sponsor: Johnson & Johnson Private Limited

PhasePhase 4
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

This description comes directly from the study's public registry record.

Talk to the study team

Study Contact  ·  844-434-4210  ·  Participate-In-This-Study1@its.jnj.com

Always discuss trial participation with your own doctor first.

Locations (10)

Cims HospitalAhmedabad, IndiaRecruiting
Post Graduate Institute of Medical Education And Research PGIMERChandigarh, IndiaRecruiting
Chennai Meenakshi Multispeciality HospitalChennai, IndiaRecruiting
All India Institute of Medical Sciences 1Gorakhpur, IndiaRecruiting
Nizams Institute of Medical SciencesHyderabad, IndiaRecruiting
P. D. Hinduja National Hospital and Research CenterMumbai, IndiaRecruiting
All India Institute of Medical SciencesNew Delhi, IndiaRecruiting
Sir Ganga Ram HospitalNew Delhi, IndiaRecruiting
All India Institute of Medical SciencesPatna, IndiaRecruiting
Jehangir Clinical Development CentrePune, IndiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07141004